CD4+CXCR4+ T Cells As a Novel Prognostic Biomarker in Patients with Idiopathic Inflammatory Myopathy-associated Interstitial Lung Disease
Overview
Authors
Affiliations
Backgroud: There is an unmet need for the development of new biomarkers for idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD).
Methods: Peripheral CD4+CXCR4+ T cells, stromal cell-derived factor-1 and Krebs von den Lungen-6 were measured in patients with IIM-ILD (n = 85) and controls. The relation to pulmonary functions, high-resolution CT scores, specific clinical phenotypes and survival was analysed. Cytokine-expression profiling of these CD4+CXCR4+ T cells and their co-culture with pulmonary fibroblasts were conducted.
Results: The peripheral percentages of CD4+CXCR4+ T cells were significantly elevated in IIM-ILD patients, and correlated with high-resolution CT score (r = 0.7136, P < 0.0001) and pulmonary function impairments, such as percentage of forced volume vital capacity (r = -0.4734, P = 0.0005). They were associated with anti-melanoma differentiation-associated gene 5 autoantibodies and the amyopathic DM phenotype. In IIM-ILD, peripheral percentages of CD4+CXCR4+ T cells ⩾30% revealed a 6-month mortality as high as 47%. These CD4+CXCR4+ T cells express high levels of IL-21 and IL-6. In vitro blockade of IL-21 signalling by neutralization of IL-21 or Janus kinase inhibitor could abolished the fibroblast proliferation.
Conclusion: Overall, peripheral CD4+CXCR4+ T cells appear to be a potentially valuable novel biomarker associated with the severity and prognosis of IIM-ILD. They promote pulmonary fibroblast proliferation via IL-21, which may herald future targeted treatments for this severe disease.
Xin H, He P, Xi B, Wang Z, Wang H, Wang F BMC Pulm Med. 2025; 25(1):40.
PMID: 39863893 PMC: 11762128. DOI: 10.1186/s12890-025-03512-4.
Guo Y, Liu H, Chen B, Zhang K, Meng L, Yan L Front Immunol. 2024; 15:1455944.
PMID: 39588376 PMC: 11586385. DOI: 10.3389/fimmu.2024.1455944.
Upadhyay S, Kumar S, Singh V, Tiwari R, Kumar A, Sundar S Expert Rev Mol Med. 2024; 1-55.
PMID: 39587036 PMC: 11707835. DOI: 10.1017/erm.2024.36.
Wang Y, Zou R, Wei J, Tang C, Wang J, Lin M Ther Adv Respir Dis. 2024; 18:17534666241294000.
PMID: 39480695 PMC: 11528585. DOI: 10.1177/17534666241294000.
Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress.
Lu X, Peng Q, Wang G Nat Rev Rheumatol. 2023; 20(1):48-62.
PMID: 38057474 DOI: 10.1038/s41584-023-01054-9.